Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2022-03-31 Regulatory Filings
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT
Regulatory Filings Classification · 95% confidence The document is a short announcement from Simcere Pharmaceutical Group Limited regarding the permission obtained from the National Medical Products Administration of China to conduct clinical trials on a drug candidate. It is labeled as a "Voluntary Announcement" and contains no financial data, no detailed report, or financial statements. The length is only 1829 characters, which is quite short and typical for an announcement rather than a full report. There is no indication of it being an earnings release, annual report, or any other detailed filing. It is not a regulatory certification or officer attestation. The content is about a clinical trial permission, which is a regulatory or operational update but does not fit into categories like Legal Proceedings or M&A. Given the nature and length, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2022-03-31 English
FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2021
Notice of Dividend Amount Classification · 100% confidence The document is titled 'FINAL DIVIDEND FOR THE YEAR ENDED DECEMBER 31, 2021' and contains detailed information about the dividend amount, payment dates, record dates, and related shareholder information. It does not contain financial statements or comprehensive financial performance data but focuses solely on dividend declaration details. The document length is 3329 characters, which is relatively short and consistent with a dividend announcement rather than a full report. Therefore, this document fits the category of a Notice of Dividend Amount (DIV).
2022-03-24 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2021
Annual Report Classification · 95% confidence The document is titled 'ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2021' and contains detailed financial highlights, business overview, management discussion and analysis, and key milestones for the full fiscal year 2021. It includes comprehensive financial data such as revenue, profit, earnings per share, and R&D costs, as well as operational and strategic information. The length is substantial (15,000 characters), indicating it is a full report rather than a brief announcement. The content aligns with an Annual Report, which covers company activity and full financial performance for the year. Therefore, the document should be classified as an Annual Report (10-K). FY 2021
2022-03-24 English
VOLUNTARY ANNOUNCEMENT IN RELATION TO THE CLINICAL TRIAL APPROVAL FOR SIM0272 ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding the clinical trial approval for a drug (SIM0272) issued by the National Medical Products Administration. It is a short announcement (3558 characters) informing shareholders and investors about a business development event, specifically regulatory approval for a clinical trial. There are no financial statements, detailed financial data, or comprehensive report content. The document does not present an annual or interim report, earnings release, or any detailed management discussion. It is not a regulatory filing in the sense of compliance or certification, nor is it a call transcript or AGM material. The content fits best as a general regulatory or business update announcement. Given the short length and nature of the content, it is not a full report but an announcement. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory or business announcements that do not fit other categories.
2022-03-22 English
VOLUNTARY ANNOUNCEMENT ON COOPERATION WITH LYNK PHARMACEUTICALS TO INTRODUCE SELECTIVE JAK1 INHIBITOR
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group Limited regarding a cooperation agreement with Lynk Pharmaceuticals to introduce a selective JAK1 inhibitor. It is an announcement of a business development event, specifically a cooperation agreement, and does not contain financial statements, audit information, voting results, or regulatory filings. The document is relatively short (3646 characters) and serves as a business update rather than a formal financial or regulatory report. Therefore, it fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other specific categories. According to the classification rules, such documents are classified as Regulatory Filings (RNS).
2022-03-18 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from Simcere Pharmaceutical Group Limited stating the date of a board meeting to consider and approve the annual results for the year ended December 31, 2021, and the recommendation on the payment of a final dividend. It does not contain the actual annual report or financial data but merely announces the meeting date and agenda. The document length is only 1596 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the 'MENU VS MEAL' rule, this is a report publication announcement or a meeting announcement related to the annual results, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2022-03-10 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.